nach oben

Die Ophthalmologie

Erschienen in:

22.02.2019 | Atropin | Leitthema

Therapieoptionen bei progredienter Myopie im Kindesalter

verfasst von: Dr. L. Joachimsen, Prof. Dr. W. A. Lagrèze

Erschienen in: Die Ophthalmologie | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Weltweit nimmt die Inzidenz der Myopie zu. Die damit einhergehende Zunahme sekundärer und visusbedrohender Augenerkrankungen wird Patienten, Augenärzte, Optometristen, Optiker und die Gesundheitssysteme vor große Herausforderungen stellen. Da eine Myopie im Kindes- und Jugendalter beginnt, kann eine Progression nur in dieser Lebensphase beeinflusst werden. Dieser Beitrag gibt einen Überblick über optische und pharmakologische Therapieoptionen, die mittlere Effektgrößen von bis zu 50 % Progressionsminderung bei vergleichsweise günstigem Nebenwirkungsprofil aufweisen.

Fricke TR, Jong M, Naidoo KS, Sankaridurg P, Naduvilath TJ, Ho SM et al (2018) Global prevalence of visual impairment associated with myopic macular degeneration and temporal trends from 2000 through 2050: systematic review, meta-analysis and modelling. Br J Ophthalmol 102(7):855–862CrossRef

Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P et al (2016) Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 123(5):1036–1042CrossRef

Williams KM, Bertelsen G, Cumberland P, Wolfram C, Verhoeven VJM, Anastasopoulos E et al (2015) Increasing prevalence of myopia in Europe and the impact of education. Ophthalmology 122(7):1489–1497CrossRef

Wesemann W (2018) Analysis of spectacle lens prescriptions shows no increase of myopia in Germany from 2000 to 2015. Ophthalmologe 115(5):409–417CrossRef

Flitcroft DI (2012) The complex interactions of retinal, optical and environmental factors in myopia aetiology. Prog Retin Eye Res 31(6):622–660CrossRef

Trier K, Munk Ribel-Madsen S, Cui D, Brøgger Christensen S (2008) Systemic 7‑methylxanthine in retarding axial eye growth and myopia progression: a 36-month pilot study. J Ocul Biol Dis Infor 1(2–4):85–93CrossRef

Jensen H (1991) Myopia progression in young school children. A prospective study of myopia progression and the effect of a trial with bifocal lenses and beta blocker eye drops. Acta Ophthalmol 200:1–79

Chua W‑H, Balakrishnan V, Chan Y‑H, Tong L, Ling Y, Quah B‑L et al (2006) Atropine for the treatment of childhood myopia. Ophthalmology 113(12):2285–2291CrossRef

Chia A, Chua WH, Cheung YB, Wong WL, Lingham A, Fong A et al (2012) Atropine for the treatment of childhood myopia: safety and efficacy of 0.5 %, 0.1 %, and 0.01 % doses (Atropine for the Treatment of Myopia 2). Ophthalmology 119(2):347–354CrossRef

10.

Chia A, Chua W‑H, Wen L, Fong A, Goon YY, Tan D (2014) Atropine for the treatment of childhood myopia: changes after stopping atropine 0.01 %, 0.1 % and 0.5. Am J Ophthalmol 157(2):451–457.e1CrossRef

11.

Yam JC, Jiang Y, Tang SM, Law AKP, Chan JJ, Wong E et al (2018) Low-concentration atropine for myopia progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05 %, 0.025 %, and 0.01 % atropine eye drops in myopia control. Ophthalmology 126:113. https://doi.org/10.1016/j.ophtha.2018.05.029 CrossRefPubMed

12.

Li S‑M, Wu S‑S, Kang M‑T, Liu Y, Jia S‑M, Li S‑Y et al (2014) Atropine slows myopia progression more in Asian than white children by meta-analysis. Optom Vis Sci 91(3):342–350PubMed

13.

Schittkowski MP, Sturm V (2018) Atropine for the prevention of progression in myopia—data, side effects, practical guidelines. Klin Monbl Augenheilkd 235(4):385–391CrossRef

14.

Huang J, Wen D, Wang Q, McAlinden C, Flitcroft I, Chen H et al (2016) Efficacy comparison of 16 interventions for myopia control in children: a network Meta-analysis. Ophthalmology 123(4):697–708CrossRef

15.

Polling JR, Eijkemans MJ, Esser J, Gilles U, Kolling GH, Schulz E et al (2009) A randomised comparison of bilateral recession versus unilateral recession-resection as surgery for infantile esotropia. Br J Ophthalmol 93(7):954–957CrossRef

16.

Diaz-Llopis M, Pinazo-Durán MD (2018) Superdiluted atropine at 0.01 % reduces progression in children and adolescents. A 5 year study of safety and effectiveness. Arch Soc Esp Oftalmol. https://doi.org/10.1016/j.oftale.2018.02.006 CrossRefPubMed

17.

Wu P‑C, Chuang M‑N, Choi J, Chen H, Wu G, Ohno-Matsui K et al (2018) Update in myopia and treatment strategy of atropine use in myopia control. Eye (Lond) 33(1):3–13CrossRef

18.

Wolffsohn JS, Calossi A, Cho P, Gifford K, Jones L, Li M et al (2016) Global trends in myopia management attitudes and strategies in clinical practice. Cont Lens Anterior Eye 39(2):106–116CrossRef

19.

Gong Q, Janowski M, Luo M, Wei H, Chen B, Yang G et al (2017) Efficacy and adverse effects of atropine in childhood myopia: a meta-analysis. Jama Ophthalmol 135(6):624–630CrossRef

20.

Cooper J, Eisenberg N, Schulman E, Wang FM (2013) Maximum atropine dose without clinical signs or symptoms. Optom Vis Sci 90(12):1467–1472CrossRef

21.

Loughman J, Flitcroft DI (2016) The acceptability and visual impact of 0.01 % atropine in a Caucasian population. Br J Ophthalmol 100(11):1525–1529CrossRef

22.

Nishiyama Y, Moriyama M, Fukamachi M, Uchida A, Miyaushiro H, Kurata A et al (2015) Side Effects of Low Dose Atropine. Nippon Ganka Gakkai Zasshi 119(11):812–816PubMed

23.

German EJ, Wood D, Hurst MA (1999) Ocular effects of antimuscarinic compounds: is clinical effect determined by binding affinity for muscarinic receptors or melanin pigment? J Ocul Pharmacol Ther 15(3):257–269CrossRef

24.

Chia A, Lu Q‑S, Tan D (2015) Five-year clinical trial on atropine for the treatment of myopia 2: myopia control with atropine 0.01 % Eyedrops. Ophthalmology 123(2):391–399CrossRef

25.

Wu P‑C, Yang Y‑H, Fang P‑C (2011) The long-term results of using low-concentration atropine eye drops for controlling myopia progression in schoolchildren. J Ocul Pharmacol Ther 27(5):461–466CrossRef

26.

Sun Y‑Y, Li S‑M, Li S‑Y, Kang M‑T, Liu L‑R, Meng B et al (2017) Effect of uncorrection versus full correction on myopia progression in 12-year-old children. Graefes Arch Clin Exp Ophthalmol 255(1):189–195CrossRef

27.

Adler D, Millodot M (2006) The possible effect of undercorrection on myopic progression in children. Clin Exp Optom 89(5):315–321CrossRef

28.

Chung K, Mohidin N, O’Leary DJ (2002) Undercorrection of myopia enhances rather than inhibits myopia progression. Vision Res 42(22):2555–2559CrossRef

29.

Walline JJ, Lindsley K, Vedula SS, Cotter SA, Mutti DO, Twelker JD (2011) Interventions to slow progression of myopia in children. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD004916.pub3 CrossRefPubMedPubMedCentral

30.

Gwiazda J, Hyman L, Hussein M, Everett D, Norton TT, Kurtz D et al (2003) A randomized clinical trial of progressive addition lenses versus single vision lenses on the progression of myopia in children. Invest Ophthalmol Vis Sci 44(4):1492–1500CrossRef

31.

Li S‑M, Ji Y‑Z, Wu S‑S, Zhan S‑Y, Wang B, Liu L‑R et al (2011) Multifocal versus single vision lenses intervention to slow progression of myopia in school-age children: a meta-analysis. Surv Ophthalmol 56(5):451–460CrossRef

32.

Lam CSY, Tang WC, Tse DY-Y, Tang YY, To CH (2014) Defocus Incorporated Soft Contact (DISC) lens slows myopia progression in Hong Kong Chinese schoolchildren: a 2-year randomised clinical trial. Br J Ophthalmol 98(1):40–45CrossRef

33.

Aller TA, Liu M, Wildsoet CF (2016) Myopia control with bifocal contact lenses: a randomized clinical trial. Optom Vis Sci 93(4):344–352CrossRef

34.

Bullimore MA (2017) The safety of soft contact lenses in children. Optom Vis Sci 94(6):638–646CrossRef

35.

Cho P, Cheung S‑W (2017) Protective role of orthokeratology in reducing risk of rapid axial elongation: a reanalysis of data from the ROMIO and TO-SEE studies. Invest Ophthalmol Vis Sci 58(3):1411–1416CrossRef

36.

Lin H‑J, Wan L, Tsai F‑J, Tsai Y‑Y, Chen L‑A, Tsai AL et al (2014) Overnight orthokeratology is comparable with atropine in controlling myopia. BMC Ophthalmol 14:40CrossRef

37.

Chen C, Cheung SW, Cho P (2013) Myopia control using toric orthokeratology (TO-SEE study). Invest Ophthalmol Vis Sci 54(10):6510–6517CrossRef

38.

Lipson MJ, Brooks MM, Koffler BH (2018) The role of orthokeratology in myopia control: a review. Eye Contact Lens 44(4):224–230CrossRef

39.

Charm J, Cho P (2013) High myopia-partial reduction ortho-k: a 2-year randomized study. Optom Vis Sci 90(6):530–539CrossRef

40.

Cho P, Cheung SW, Edwards M (2005) The longitudinal orthokeratology research in children (LORIC) in Hong Kong: a pilot study on refractive changes and myopic control. Curr Eye Res 30(1):71–80CrossRef

41.

Hiraoka T, Kakita T, Okamoto F, Takahashi H, Oshika T (2012) Long-term effect of overnight orthokeratology on axial length elongation in childhood myopia: a 5-year follow-up study. Invest Ophthalmol Vis Sci 53(7):3913–3919CrossRef

42.

Kakita T, Hiraoka T, Oshika T (2011) Influence of overnight orthokeratology on axial elongation in childhood myopia. Invest Ophthalmol Vis Sci 52(5):2170–2174CrossRef

43.

Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutiérrez-Ortega R (2012) Myopia control with orthokeratology contact lenses in Spain: refractive and biometric changes. Invest Ophthalmol Vis Sci 53(8):5060–5065CrossRef

44.

Walline JJ, Jones LA, Sinnott LT (2009) Corneal reshaping and myopia progression. Br J Ophthalmol 93(9):1181–1185CrossRef

45.

Tsukiyama J, Miyamoto Y, Higaki S, Fukuda M, Shimomura Y (2008) Changes in the anterior and posterior radii of the corneal curvature and anterior chamber depth by orthokeratology. Eye Contact Lens 34(1):17–20CrossRef

46.

Cheung S‑W, Cho P (2013) Validity of axial length measurements for monitoring myopic progression in orthokeratology. Invest Ophthalmol Vis Sci 54(3):1613–1615CrossRef

47.

Cho P, Cheung SW (2017) Discontinuation of orthokeratology on eyeball elongation (DOEE). Cont Lens Anterior Eye 40(2):82–87CrossRef

48.

Watt KG, Swarbrick HA (2007) Trends in microbial keratitis associated with orthokeratology. Eye Contact Lens 33(6 Pt 2):373–377 (discussion 382)CrossRef

49.

Li S‑M, Kang M‑T, Wu S‑S, Liu L‑R, Li H, Chen Z et al (2016) Efficacy, safety and acceptability of orthokeratology on slowing axial elongation in myopic children by meta-analysis. Curr Eye Res 41(5):600–608CrossRef

50.

Bullimore MA, Sinnott LT, Jones-Jordan LA (2013) The risk of microbial keratitis with overnight corneal reshaping lenses. Optom Vis Sci 90(9):937–944CrossRef

51.

Liu YM, Xie P (2016) The safety of orthokeratology—a systematic review. Eye Contact Lens 42(1):35–42CrossRef

Titel: Therapieoptionen bei progredienter Myopie im Kindesalter
verfasst von: Dr. L. Joachimsen
Prof. Dr. W. A. Lagrèze
Publikationsdatum: 22.02.2019
Verlag: Springer Medizin
Schlagwort: Atropin
Erschienen in: Die Ophthalmologie / Ausgabe 6/2019
Print ISSN: 2731-720X
Elektronische ISSN: 2731-7218
DOI: https://doi.org/10.1007/s00347-019-0873-7

Neu im Fachgebiet Augenheilkunde

08.04.2024 | Therapieverfahren in der Augenheilkunde | CME

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Therapieoptionen bei progredienter Myopie im Kindesalter

Zusammenfassung

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

Bestmögliche Wundheilung der Kornea dank optimaler pharmakologischer Therapie

Update Augenheilkunde

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2019

Stellenwert der Vitrektomie bei Endophthalmitis

Mitteilungen der DOG

Prävention der Myopie

Morphologische retinale Charakteristika von Patienten mit einer Sehbehinderung infolge eines diabetischen Makulaödems

Epidemiologie und Anatomie der Myopie

Glaukome im stationären Leistungsgeschehen in Deutschland in 2015

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

Bestmögliche Wundheilung der Kornea dank optimaler pharmakologischer Therapie

Update Augenheilkunde